Cabot Corporation Stock Price and Value Analysis

Cabot Corporation (NYSE:CBT) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Cabot Corporation to reach your target.

Target type

CBT Free Cash Flow Trend

Free Cash Flow trendline for CBT
Free Cash Flow trendline for Cabot Corporation
CSV

Based on historical returns, we believe that Cabot Corporation can grow its free cash at a rate of about 5%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company is making money at a decent rate.
  • This stock is available at a great discount!
  • This company has wild ups and downs.
  • This company is less known than others.
  • This company pays no dividend.

Inside the CBT Numbers

CBT Price
(Cabot Corporation stock price per share)
$70.48
[?] CBT Fair Price
(based on intrinsic value)
$201.86
[?] CBT Safety Price (based on a variable margin of safety) $121.12
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 31% higher than other Basic Materials stocks
[?] PE Ratio versus Industry 0% lower than other Specialty Chemicals stocks
[?] Cash Yield 14.95%
[?] Free Cash Flow Jitter 74%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

Recent Insider Activity

Open-market buys and sells reported by Cabot Corporation's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2025-08-14 Keohane Sean D (President and CEO) Sell 2,369 $79.63
2025-08-14 Keohane Sean D (President and CEO) Sell 24,086 $79.25
2025-08-14 Keohane Sean D (President and CEO) Sell 7,677 $79.62
2025-08-14 Keohane Sean D (President and CEO) Sell 80,304 $79.24
2024-11-13 Zhu Jeff Ji (Executive Vice President) Sell 14,566 $113.25
2024-11-13 Dumont Lisa M (VP, Controller & CAO) Sell 865 $111.74
2024-11-11 Kalkstein Hobart (Executive Vice President) Sell 12,178 $115.00
2024-11-11 Kalkstein Hobart (Executive Vice President) Sell 8,390 $115.02
2024-11-11 Kalkstein Hobart (Executive Vice President) Sell 14,191 $115.54
2024-09-03 Keohane Sean D (President and CEO) Sell 17,865 $101.23

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 5,202,043 shares shorted. With 50,482,467 shares available for purchase and an average trading volume over the past 10 trading days of 358,970, it would take at least 14.5 days for all of the short holders to cover their shorts.

What does this mean to you? At this volume, it'll take more than two trading weeks for shorts to cover. This may indicate a short squeeze play would work! If this stock has good fundamentals and it'll take a while for the short holders to cover, buying now could net you bigger short-term technical gains if and as the price rises.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2008 16040 -75
2009 16040 247
2010 16040 111
2011 16040 34.2
2012 16040 230
2013 16040 221
2014 16040 104
2015 16040 282
2016 16040 198
2017 16040 181
2018 16040 138
2019 16040 192
2020 16040 195
2021 16040 58
2022 16040 -112
2023 16040 380
2024 16040 474
2025 16040 432

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 14 fiscal years from 2008 to 2025 with positive net income, operating cash flow totaled $5,129 million against net income of $3,383 million, or 1.52 times. Net income was negative in 4 of the 18 years, and those years are left out of the ratio.

In 2025, operating cash flow was 2.01 times net income, compared with 1.55 times for the earliest three years (2008 to 2010).

In 2025, capital expenditures were $274 million, 41.2% of operating cash flow of $665 million, which leaves an estimated $391 million after capex. Across the 18 years with reported capex, it averaged 53.4% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2008 86 124 199 1.44
2009 -77 399 106 n/a
2010 154 249 108 1.62
2011 236 195 230 0.83
2012 388 415 281 1.07
2013 153 419 264 2.74
2014 199 315 171 1.58
2015 -334 499 141 n/a
2016 147 392 112 2.67
2017 248 348 147 1.40
2018 -113 298 229 n/a
2019 157 363 224 2.31
2020 -238 377 200 n/a
2021 250 257 195 1.03
2022 209 100 211 0.48
2023 445 595 244 1.34
2024 380 692 241 1.82
2025 331 665 274 2.01

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $2,136 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $823 million, 38.5% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 8 of those 10 years.

In 9 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $906 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, dividends and cash spent repurchasing shares together were $264 million, 61.1% of estimated free cash flow of $432 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 198 65 45 110 55.5%
2017 181 77 61 138 76.2%
2018 138 80 142 222 160.9%
2019 192 80 173 253 131.5%
2020 195 80 44 124 63.7%
2021 58 80 3 83 143.1%
2022 -112 84 53 137 n/a
2023 380 88 98 186 48.9%
2024 474 93 172 265 55.9%
2025 432 96 168 264 61.1%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $3,191 million in 2008 and $3,713 million in 2025, a compound annual growth rate of 0.9% over 17 years.

Revenue fell 7.0% from 2024 to 2025.

Our estimated free cash flow was $432 million in 2025, 11.6% of revenue. In 2008 the estimated margin was negative 2.4%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2008 3,191 -75 -2.4%
2009 2,108 247 11.7%
2010 2,716 111 4.1%
2011 3,102 34.2 1.1%
2012 3,291 230 7.0%
2013 3,456 221 6.4%
2014 3,647 104 2.9%
2015 2,871 282 9.8%
2016 2,411 198 8.2%
2017 2,717 181 6.7%
2018 3,242 138 4.3%
2019 3,337 192 5.8%
2020 2,614 195 7.4%
2021 3,409 58 1.7%
2022 4,321 -112 -2.6%
2023 3,931 380 9.7%
2024 3,994 474 11.9%
2025 3,713 432 11.6%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $258 million against total liabilities of $2,110 million, or 12.2% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 55.3% of total assets in 2025, compared with 53.8% in 2009, an increase of 1.5 percentage points.

Stockholders equity was $1,705 million in 2025, compared with $1,237 million in 2009, a rise of 37.8%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 16.6% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2009 2,676 304 1,439 1,237
2010 2,886 387 1,469 1,417
2011 3,141 286 1,525 1,616
2012 4,399 120 2,460 1,939
2013 4,233 95 2,150 2,083
2014 4,084 67 2,020 2,064
2015 3,063 77 1,718 1,338
2016 3,052 200 1,646 1,372
2017 3,338 280 1,713 1,625
2018 3,244 175 1,965 1,279
2019 3,004 169 1,870 1,134
2020 2,781 151 1,967 814
2021 3,306 168 2,216 1,090
2022 3,525 206 2,493 1,032
2023 3,604 238 2,197 1,407
2024 3,736 223 2,146 1,590
2025 3,815 258 2,110 1,705

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $70.48, our model's value equals that price if free cash flow grows an average of -15.7 percent a year over the 10 projection years. Our model assumes 5.0 percent a year for this stock, so the price implies growth of -15.7 percent, which is below the 5.0 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

A negative rate means the price matches our model's value only if free cash flow shrinks by that average each year over the 10 years.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $541 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $56.38 -22.9%
Current price $70.48 -15.7%
20 percent above the current price $84.58 -11.1%
Our model (stored fair price) $201.86 5.0%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Cabot Corporation is priced at $70.48, under its safe value estimate of $121.12 (fair value: $201.86).

Only 16 of the 18 fiscal years under Cabot Corporation's current filer show positive free cash flow.

The latest three years average $429 million in free cash flow against $94.3 million for the earliest three, which is a sharp rise.

Free cash flow is volatile from year to year, with a variability measure of 74%.

Our value investing guide explains how to test these numbers against the filings themselves.

No dividend yield is recorded for Cabot Corporation in our data.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 31% above the average for stocks in the Basic Materials sector.

Its trailing P/E ratio is in line with the average for stocks in the Specialty Chemicals industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Specialty Chemicals industry, the ones closest in market capitalization to Cabot Corporation, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Cabot Corporation (CBT) 3,618 17.5 - 15.0% 65% below
WD-40 Company (WDFC) 2,929 36.0 1.9% 1.9% 27% above
Hexcel Corporation (HXL) 5,520 32.8 0.9% 1.3% 139% above
Eastman Chemical Company (EMN) 6,719 10.5 5.4% 22.8% 77% below
AdvanSix (ASIX) 347 - 4.7% - 57% below
Element Solutions Inc (ESI) 7,162 34.7 1.0% 1.3% 80% above
Flexible Solutions International (FSI) 74.9 - - - 92% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 16040.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 2 of the 18 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: CBT annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in CBT

Does Cabot Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: CBT

This example shows how we apply the Trendshare checklist to CBT: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 70.48
    • Market cap: $3.6B
    • EPS: 4.02
  2. Step 2 — Valuation checks

    • P/E: 17.532
    • FCF yield: 15.0%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.